Solid Biosciences Inc. Announces $85 Million Common Stock Offering Under New Prospectus Supplement

Reuters
16 May
<a href="https://laohu8.com/S/SLDB">Solid Biosciences</a> Inc. Announces $85 Million Common Stock Offering Under New Prospectus Supplement

Solid Biosciences Inc. has announced the filing of a prospectus supplement related to the offer and sale of up to $85 million in common stock shares. This move is part of an amended sales agreement with Jefferies LLC. Previously, the company had issued and sold shares for gross proceeds of approximately $10.5 million under a prior prospectus. Legal counsel from Wilmer Cutler Pickering Hale and Dorr LLP has provided a legal opinion on the shares, ensuring compliance with applicable registration requirements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Solid Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-072792), on May 15, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10